Abeona Therapeutics SVP sells $34,681 in company stock

Abeona Therapeutics' Senior Vice President and Chief Legal Officer, Brendan M. O’Malley, sold 6,727 shares of the company's common stock on September 29, 2026, for a total value of $34,681. The sale was made to cover tax obligations from vesting restricted stock awards. The transaction occurred as ABEO stock was trading at $5.16, down nearly 7% from the previous week.

Following the sale, O’Malley retained 421,226 shares of the company's common stock. Analysts note that the stock appears undervalued based on Fair Value calculations, with 11 ProTips and insights available from InvestingPro, including information on the company's cash position and profitability outlook. Meanwhile, Abeona Therapeutics reported a 31% increase in sales of its lead therapy, ZEVASKYN, in Q2 2026, but revenue fell short of Wall Street's expectations at $11.4 million, resulting in a net loss of $20.2 million.

The FDA approved FAYUVI, a gene therapy developed by Abeona and out-licensed to Ultragenyx Pharmaceutical, for treating Sanfilippo syndrome type A, leading to an increased price target from Cantor Fitzgerald and positive ratings from H.C. Wainwright and Roth/MKM.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.